# BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy

> **NCT07755904** · PHASE3 · RECRUITING · sponsor: **Braveheart Bio, Inc.** · enrollment: 210 (estimated)

## Conditions studied

- Cardiomyopathy, Hypertrophic Obstructive

## Interventions

- **DRUG:** BHB-1893
- **DRUG:** Metoprolol

## Key facts

- **NCT ID:** NCT07755904
- **Lead sponsor:** Braveheart Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-02
- **Primary completion:** 2028-10
- **Final completion:** 2028-11
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07755904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07755904, "BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07755904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*